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Summary  The  primary  objective  of  this  analysis  was  to  evaluate  group  2  car-
bapenem  usage  and  to  model  the  impact  that  a  formalized  de-escalation  protocol
to  ertapenem  could  potentially  have  on  group  2  carbapenem  usage  in  the  hope  of
alleviating  the  selective  pressure  on  Acinetobacter  and  Pseudomonas. This  anal-
ysis  was  conducted  in  three  hospitals  within  the  Detroit  Medical  Center  in  2009.
Patients  were  considered  candidates  for  de-escalation  of  carbapenem  therapy  when
a  group  2  carbapenem  was  utilized  to  treat  Enterobacteriaceae,  such  as  extended
spectrum  -lactamase  (ESBL)-producing  organisms,  or  if  cultures  were  negative  in
non-intensive  care  unit  (ICU)  patients.  In  total,  179  patients  (28%)  and  1074  patient-
days  (29%)  were  deemed  eligible  for  de-escalation  according  to  our  pre-deﬁned
criteria.  We  concluded  that  preferential  utilization  of  ertapenem  in  appropriate
patients  warranting  carbapenem  therapy  has  the  potential  to  signiﬁcantly  decrease
group  2  carbapenem  usage  at  our  institution.
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eropenem,  imipenem,  and  doripenem,  among
cinetobacter baumannii  and  Pseudomonas
eruginosa  poses  a  signiﬁcant  therapeutic
 Sciences. Published by Elsevier Ltd. All rights reserved.
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totential  impact  of  carbapenem  de-escalation  
hallenge.  Often,  the  only  remaining  therapeutic
ptions are  tigecycline  (for  Acinetobacter  and  not
seudomonas) or  colistin-based  regimens,  which
re associated  with  suboptimal  outcomes  and  high
ates of  toxicity  [1—3]. Ertapenem  is  a  group  1
arbapenem  that  retains  good  in  vitro  activity
gainst Enterobacteriaceae,  including  extended
pectrum -lactamase-producers  (ESBLs)  and  ampC
yperproducers  [4],  but  has  no  appreciable  activity
gainst  A.  baumannii  or  P.  aeruginosa. Because  of
his lack  of  activity  against  non-lactose-fermenting
ram-negative  organisms,  there  is  a  potential
eneﬁt, in  terms  of  antimicrobial  resistance,  of
sing ertapenem  in  place  of  group  2  carbapenems
o reduce  the  selective  antimicrobial  pressure.
ecent studies  have  reported  that  the  suscep-
ibility of  P.  aeruginosa  to  imipenem  remained
table [5—7]  and,  in  some  cases,  even  improved  [8]
fter  the  introduction  of  ertapenem  into  hospital
ormularies. However,  it  is  important  to  note  that
irect causality  between  ertapenem  introduction
nd the  improved  susceptibilities  in  P.  aeruginosa
hould not  be  assumed,  as  increases  or  decreases
n susceptibility  are  multifactorial.  Despite  this
aveat,  evidence  suggests  that,  at  the  very  least,
ntroduction  of  ertapenem  does  not  negatively
ffect imipenem  susceptibility  in  P.  aeruginosa.
The aims  of this  study  were  to  analyze  the  uti-
ization of  group  2  carbapenems  in  a  large  tertiary
ealthcare system  to  identify  patients  in  whom  de-
scalation  from  group  2  carbapenem  to  ertapenem
ould have  been  appropriate  and  to  model  the
otential impact  of  a  formalized  carbapenem  de-
scalation  program  on  carbapenem  utilization.
aterials and methods
 retrospective  analysis  of  all  carbapenem  use  at
hree hospitals  within  the  Detroit  Medical  Cen-
er (DMC)  in  2009  was  performed.  The  DMC  is  a
niversity-afﬁliated  eight-hospital  tertiary  health-
are system  with  more  than  2200  inpatient  beds
n metropolitan  Detroit.  For  the  purposes  of  these
nalyses,  only  patients  at  Detroit  Receiving  Hos-
ital, Harper  University  Hospital,  and  Sinai-Grace
ospital were  included.  These  three  hospitals  have
 total  of  1180  beds.  The  pharmacy  database  was
ueried to  identify  all  patients  at  these  institutions
ho received  any  carbapenem  in  the  2009  calendar
ear.  The  medical  records  for  these  patients  were
hen accessed,  and  a  standardized  data  collection
orm was  utilized  to  extract  the  patient  demograph-
cs, comorbid  conditions,  intensive  care  unit  (ICU)
tatus, relevant  laboratory  values,  indications  for
arbapenem  therapy,  microbiological  results,  and
he doses  and  durations  of  therapy.
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The  charts  of  the  patients  who  received  group  2
arbapenems  were  analyzed  to  determine  whether
e-escalation  to  ertapenem  therapy  would  have
een appropriate.  De-escalation  was  considered
ppropriate if  the  patient  was  receiving  therapy
or infections  due  to  an  ESBL,  an  ampC-producing
rganism,  or  other  carbapenem-susceptible  Entero-
acteriaceae  or  if  the  culture  was  negative  and
he patient  continued  to  receive  therapy;  addition-
lly,  the  patient  had  to  be  located  on  the  general
edical  ﬂoor.  Patients  were  deemed  ineligible
or de-escalation  to  ertapenem  if P.  aeruginosa,
. baumannii, or  penicillin-susceptible  Enterococ-
us spp.  were  recovered,  if  the  cultures  were
egative and  they  resided  in  the  ICU  (as  many
linicians desire  activity  against  P.  aeruginosa  in
n ICU  setting  even  if  cultures  are  negative)  if
hey received  carbapenem  therapy  for  ≤72  h fol-
owing culture,  or  if  the  patient  had  cystic  ﬁbrosis,
entral  nervous  system  infection,  febrile  neutrope-
ia, osteomyelitis,  or  infection  due  to  Nocardia
pp. If patients  met  the  eligibility  criteria  for  de-
scalation  to  ertapenem,  the  initial  72  h  of group  2
arbapenem  therapy  after  culture  were  considered
ppropriate, as  cultures  are  often  ﬁnalized  after
2 h.
Analysis  was  performed  to  assess  the  impact
hat a carbapenem  de-escalation  program  would
ave on  the  amounts  of  group  2  carbapenem  and
rtapenem  utilized  during  the  study  period.
esults
arbapenem utilization
 total  of  557  patients  received  meropenem  during
he study  period,  accounting  for  3601  patient-days
f therapy.  Imipenem  was  used  in  42  patients  for
 total  of  223  patient-days,  while  ertapenem  was
tilized  in  156  patients  for  829  patient-days  of
herapy.
nalysis of group 2 carbapenem usage
ables  1  and  2  show  detailed  breakdowns  of
he group  2 carbapenem  usage  and  cases  where
e-escalation to  ertapenem  would  have  been
ppropriate (n =  1074  patient-days,  28%  of  total
sage) or  inappropriate  (n  = 2232  patient-days,  58%
f total  usage).  For  patients  in  whom  de-escalation
herapy would  have  been  appropriate,  the  ﬁrst
2 h  of  the  group  2  carbapenem  therapy  after  cul-
ure was  considered  appropriate,  and  this  time
ccounted  for  the  remaining  528  patient-days  (14%)
f usage.
52  
Table  1  Incidences  of  group  2  usage  where
de-escalation  to  ertapenem  would  have  been
inappropriate.
Indication  Patients  Patient-days
A.  baumannii  or  P.
aeruginosa  coverage
neededa
134  1152  (32%)
ICU  patient 56  483  (12%)
Received  agent  for  ≤72  h 217  451  (12%)
Cystic  ﬁbrosis  patient  6  48  (1%)
Central  nervous  system
infection
4 40  (1%)
Nocardia  infection  2  31  (1%)
Febrile  neutropenia  2  20  (1%)
Osteomyelitis  1  7  (0.2%)
Total  423  2232  (58%)
a Also included scenarios in which carbapenem ther-
apy + enterococcal activity was needed.
Table  2  Incidences  of  group  2  usage  when
de-escalation  to  ertapenem  would  have  been
appropriate.
Indication  Patients  Patient-days
Infection  due  to  ESBL,
ampC  hyperproducer,  or
more  susceptible
Enterobacteriaceae
101  59  (16%)
Cultures  (−),  non-ICU
patient
75  476  (12%)
Total 176  1074  (28%)
For patients in whom de-escalation therapy would have been
appropriate, the ﬁrst 72 h of group 2 carbapenem therapy
after culture were considered appropriate (528 patient-days,
14%).
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aThe  two  most  common  indications  resulting  in
continued  group  2  usage  where  de-escalation  would
not have  been  appropriate  were  the  need  for  A.
baumannii, P.  aeruginosa, or  E.  faecalis  coverage
based on  the  culture  results  (32%  of  the  total  group
2 carbapenem  usage)  and  negative  cultures  recov-
ered from  patients  in  the  ICU  (12%  of  the  total
usage). Based  on  our  predeﬁned  criteria,  176  (29%)
patients  could  have  been  de-escalated  from  group  2
carbapenem  to  ertapenem,  and  1074  (28%)  days  of
group 2  carbapenem  usage  could  have  been  spared.
DiscussionCarbapenem  resistance  in  Pseudomonas  and  Acine-
tobacter  is  a  growing  problem  and  is  recognized
o
t
u
bF.  Ahmad  et  al.
s  a major  public  health  threat  [9]. Although  rates
f carbapenem  resistance  among  Pseudomonas  spp.
ave remained  stable,  a marked  increase  was  noted
n carbapenem  resistance  among  Acinetobacter
aumannii over  the  past  5  years  at  the  DMC  [10].
trategies to  decrease  group  2  carbapenem  use  and
o reduce  selective  antimicrobial  pressure  on  Pseu-
omonas  and  A.  baumannii  have  been  explored.
This analysis  revealed  that  more  than  1000
atient-days of  group  2  carbapenem  use  during
 12-month  period  (approximately  30%  of  car-
apenem use)  in  our  health  system  could  have  been
voided if  a de-escalation  program  had  been  in
lace to  use  ertapenem  in  place  of  group  2  car-
apenems in  appropriate  clinical  scenarios.  This
ype of  drastic  reduction  has  the  potential  to  sig-
iﬁcantly  alleviate  some  of  the  selective  pressure
n A.  baumannii  and  P.  aeruginosa. Based  on  these
ndings, our  institution  has  since  implemented  this
e-escalation  protocol.
There  are  important  limitations  of  this  analy-
is that  warrant  mentioning.  The  major  limitation
f our  analysis  is that  some  might  disagree  with
he criteria  used  to  determine  the  appropriate  and
nappropriate  de-escalation  opportunities;  how-
ver, it  would  be  easy  to  modify  this  analysis  with
riteria  that  others  might  consider  more  appro-
riate. Another  important  limitation  is that  we
id not  analyze  the  impact  of  such  a program
n antimicrobial  costs.  As  imipenem-cilistatin  and
eropenem  are  now  both  generic,  while  ertapenem
emains branded,  there  might  be  signiﬁcant  antibi-
tic cost  increases  associated  with  such  a  switch.
epending on  the  formulary  preferred  group  2
arbapenem  and  the  institution’s  dosing  strategy
or that  agent,  ertapenem  can  be  anywhere  from
20-$40  more  expensive  per  day.  Therefore,  if
074 days  of  group  2  carbapenem  therapy  were
witched  to  ertapenem,  antibiotic  costs  might
ncrease by  $21,480—$42,960  for  an  institution.
owever, these  costs  might  be  offset  by  reductions
n the  frequency  of  Gram-negative  bacilli  infec-
ions that  are  resistant  to  group  2  carbapenems.
hile cost  is not  the  primary  driver  of  steward-
hip programs,  it  would  still  need  to  be  taken
nto consideration.  Finally,  this  model  assumes  that
tewardship  programs  would  be  able  to  de-escalate
ll eligible  patients,  and  it is  likely  that  pre-
cribers would  not  be  willing  to  de-escalate  in  some
nstances.
This study  reports  a simple  and  organized
pproach  that  an  institution  can  follow  to  assess  the
pportunities  for  optimizing  carbapenem  utiliza-
ion and  limiting  unnecessary  group  2  carbapenem
sage. The  implementation  of  a formalized  car-
apenem  de-escalation  program  has  the  potential
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o  signiﬁcantly  reduce  unnecessary  utilization  of
roup 2 carbapenems  and,  therefore,  to  potentially
imit the  emergence  of  carbapenem  resistance.
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